Drug intelligence / Profile preview

gallium Ga 68 tilmanocept

Development stage
Phase 3
Lead developer
Navidea Biopharmaceuticals
Modality
Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration
Intravenous, Subcutaneous, Intradermal, Peritumoral, Intratumoral
01

Overview

Gallium Ga 68 tilmanocept is a radiopharmaceutical diagnostic agent consisting of the synthetic molecule tilmanocept labeled with the positron-emitting radioisotope gallium-68. Tilmanocept is a mannosylated dextran compound that binds with high affinity to CD206 (macrophage mannose receptor), which is highly expressed on the surface of macrophages and dendritic cells, particularly in lymphatic tissue. When labeled with gallium-68, it enables targeted PET imaging for sentinel lymph node mapping and detection of metastatic spread in cancers such as thyroid carcinoma and endometrial carcinoma. The agent provides high specificity for sentinel nodes, facilitating image-guided tumor resection and lymphadenectomy. It has also been investigated for imaging atherosclerotic plaques due to its ability to target macrophage-rich tissues[1][2][5][7].

Other names
gallium Ga 68 tilmanoceptgallium-68-labeled tilmanoceptgallium68-labeled tilmanoceptgallium 68-labeled tilmanocept
02

Targets

MRC1 (Mannose Receptor C-type 1)

Beyond the preview

Go deeper on gallium Ga 68 tilmanocept.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on gallium Ga 68 tilmanocept.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call